Identifying genetic factors that lead to blood clots traveling to the lungs in patients with deep vein thrombosis.
Genetic Discovery and Functional Validation to Identify Precursors of Clot Embolization in those with a Deep Vein Thrombosis
This study is looking at how certain genes might affect the risk of blood clots traveling from your legs to your lungs, which can be really serious, and it's for people who have had deep vein thrombosis (DVT) to help find out who might be at higher risk for these complications.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10807021 on NIH RePORTER |
What this research studies
This research investigates the genetic variations that may contribute to the risk of blood clots, specifically how they can travel from the deep veins to the lungs, causing serious complications like pulmonary embolism. By analyzing genetic data from patients with deep vein thrombosis (DVT), the study aims to uncover new genetic markers that could predict which patients are at higher risk for these dangerous events. The approach includes both genetic discovery and functional validation to understand the biological mechanisms involved. Patients may be asked to provide genetic samples and health information to help identify these risk factors.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with deep vein thrombosis who may be at risk for pulmonary embolism.
Not a fit: Patients who do not have deep vein thrombosis or those with other unrelated conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better risk assessment and personalized treatment strategies for patients with deep vein thrombosis.
How similar studies have performed: Previous research has identified genetic factors related to blood clotting, suggesting that this approach has potential for success in uncovering new risk markers.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Smith, Nicholas L — University of Washington
- Study coordinator: Smith, Nicholas L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.